Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Trifluridine-tipiracil hydrochloride + XB2001 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Trifluridine-tipiracil hydrochloride | Lonsurf | TAS-102|TAS102|TAS 102|S 95005|S95005|S-95005 | Lonsurf (trifluridine/tipiracil hydrochloride) is an oral combination comprised of TFT and a thymidine phosphorylase inhibitor, which can result in DNA fragmentation thereby preventing angiogenesis and tumor growth (PMID: 29226002). Lonsurf (trifluridine/tipiracil hydrochloride) is FDA-approved for use in patients with colorectal cancer, gastric or gastroesophageal junction adenocarcinoma, and in combination with Avastin (bevacizumab) in patients with previously-treated metastatic colorectal cancer (FDA.gov). | |
XB2001 | XB-2001|XB 2001|Vilamakitug | XB2001 is a monoclonal antibody that targets interleukin-1 alpha (IL1a), potentially resulting in decreased angiogenesis and reduced tumor formation (Ann Oncol (2024) 35 (suppl_1): S26, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05201352 | Phase Ib/II | Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride + XB2001 | Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1alpha True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN) | Recruiting | FRA | 0 |